Haleon (NYSE:HLN) Lowered to “Hold” Rating by Rothschild & Co Redburn

Rothschild & Co Redburn downgraded shares of Haleon (NYSE:HLN) from a strong-buy rating to a hold rating in a research note released on Tuesday,Zacks.com reports.

A number of other equities research analysts have also issued reports on the company. Wall Street Zen raised Haleon from a “hold” rating to a “buy” rating in a research report on Saturday, March 21st. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Haleon in a research report on Thursday, April 30th. Finally, Argus raised Haleon to a “strong-buy” rating in a research report on Tuesday, March 17th. Two investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Haleon has an average rating of “Moderate Buy”.

Haleon Trading Up 0.2%

NYSE HLN opened at $9.09 on Tuesday. The firm has a market cap of $40.20 billion, a P/E ratio of 23.30, a P/E/G ratio of 2.07 and a beta of 0.13. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.92 and a quick ratio of 0.71. The stock’s 50-day moving average is $9.31 and its 200-day moving average is $9.90. Haleon has a one year low of $8.65 and a one year high of $11.28.

Haleon (NYSE:HLN) last released its quarterly earnings results on Saturday, February 14th. The company reported $6.32 EPS for the quarter. The business had revenue of $3.65 billion for the quarter. Sell-side analysts anticipate that Haleon will post 0.56 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Western Wealth Management LLC acquired a new position in shares of Haleon during the 1st quarter worth approximately $29,000. Parkside Financial Bank & Trust increased its holdings in shares of Haleon by 101.3% during the 4th quarter. Parkside Financial Bank & Trust now owns 2,847 shares of the company’s stock worth $29,000 after acquiring an additional 1,433 shares during the last quarter. Annis Gardner Whiting Capital Advisors LLC increased its holdings in shares of Haleon by 402.0% during the 1st quarter. Annis Gardner Whiting Capital Advisors LLC now owns 3,002 shares of the company’s stock worth $30,000 after acquiring an additional 2,404 shares during the last quarter. Stance Capital LLC acquired a new position in shares of Haleon during the 3rd quarter worth approximately $34,000. Finally, Geneos Wealth Management Inc. increased its holdings in shares of Haleon by 33.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock worth $50,000 after acquiring an additional 1,203 shares during the last quarter. 6.67% of the stock is currently owned by institutional investors.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.